Work

NAT10 drives hepatocellular carcinoma progression through SQLE-mediated cholesterol biosynthesis and is targetable by remodelin

Year: 2025

Type: article

Abstract: experiments confirmed that inhibition of NAT10 reduces cellular cholesterol levels and suppresses tumorigenesis. Notably, the NAT10 inhibitor remodelin effectively curtailed HCC progression. Our findings identify NAT10 as a key metabolic regulator in HCC and propose targeting the NAT10-SQLE-cholesterol axis as a promising therapeutic strategy.

Source: iScience

DOI: 10.1016/j.isci.2025.114488

Authors: Yumeng Wang, Xun Yang, Yihong Dong, Xinxin Yang, Yunjing Hou, Qiang Fu, Jun Yan, Yulu Du, Qingxin Zhang, Yunfei Zhou, Aodi Wu, Shuyuan Chang, Jianwen Xu, Chunhui Zhang, Xiaoyang Hu, Hongxue Meng, Wei Sun, Dabin Liu

Institutions: Harbin Medical University, Fourth Affiliated Hospital of Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Heilongjiang University of Chinese Medicine, Peking University People's Hospital

Language: English

Topic: Cancer, Lipids, and Metabolism

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,240

Funders: Harbin Medical University, Harbin Medical University Cancer Hospital, National Natural Science Foundation of China

Awards: G1162791472, G1448349553, G1922167455, G5050694055, G7923629424

OpenAlex ID: W7116096253

FWCI: 0.65

Cites: 44

Cited by: 2

Related to: